The recent verdict in a case involving the pain reliever Vioxx demonstrates how junk science can corrupt drug litigation.

The FDA's recent move was a giant step toward a calamitous new drug approval policy.

The American tort liability systemworks badly when it gets infected by junk science.

New research findings and a thorough reassessment of older research indicate that drugs like Vioxx can have many important benefits and great potential for addressing serious problems.

Post-approval drug safety surveillance is an extraordinarily difficult task.The Vioxx episode has probably made it more difficult for the Food and Drug Administration to do its job.

It would be too easy, in an effort to cut costs, to constrict the pipeline that is producing one new wonder drug after another.

Bill Clinton's proposed drug benefit for Medicare recipients is predicated on driving down the cost of drugs that elderly Americans need.

The FDAAmendments Act of 2007 will bring the most important changes in FDA regulation in at least a decade, but it is an unnecessary law.